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Yokukansan (YKS), a traditional Japanese Kampo medicine, has indications for use
in night crying and irritability in children, as well as neurosis and insomnia. It is
currently also used for the remedy of the behavioral and psychological symptoms of
dementia (BPSD), such as aggressiveness, agitation, and hallucinations. In parallel with
clinical evidence, a significant amount of fundamental researches have been undertaken
to clarify the neuropsychopharmacological efficacies of YKS, with approximately 70
articles, including our own, being published to date. Recently, we reviewed the
neuropharmacological mechanisms of YKS, including its effects on glutamatergic,
serotonergic, and dopaminergic neurotransmission, and pharmacokinetics of the
ingredients responsible for the effects. This review is aimed to integrate the information
regarding the psychopharmacological effects of YKS with the brain regions known to be
affected, to facilitate our understanding of the clinical efficacy of YKS. In this review, we
first show that YKS has several effects that act to improve symptoms that are similar to
BPSDs, like aggressiveness, hallucinations, anxiety, and sleep disturbance, as well as
symptoms like tardive dyskinesia and cognitive deficits. We next provide the evidence
showing that YKS can interact with various brain regions, including the cerebral cortex,
hippocampus, striatum, and spinal cord, dysfunctions of which are related to psychiatric
symptoms, cognitive deficits, abnormal behaviors, and dysesthesia. In addition, the
major active ingredients of YKS, geissoschizine methyl ether and 18β-glycyrrhetinic acid,
are shown to predominantly bind to the frontal cortex and hippocampus, respectively.
Our findings suggest that YKS has multiple psychopharmacological effects, and that
these are probably mediated by interactions among several brain regions. In this review,
we summarize the available information about the valuable effects of a multicomponent
medicine YKS on complex neural networks.
Keywords: yokukansan, Kampo medicine, multiple psychopharmacological effects, responsible brain regions,
behavioral and psychological symptoms of dementia (BPSD)
INTRODUCTION
The traditional Japanese Kampo medicine Yokukansan (YKS) has been approved by the Japanese
Ministry of Health, Labor, and Welfare, and has indication for neurosis, insomnia, and children’s
night crying and irritability. In recent year, this remedy has been used for treating the behavioral
and psychological symptoms of dementia (BPSD), such as aggressiveness and hallucinations,
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which are frequently observed in patients with Alzheimer’s
disease, dementia with Lewy body, vascular dementia, and
so on, without a serious side effect (Iwasaki et al., 2005;
Mizukami et al., 2009; Monji et al., 2009; Okahara et al.,
2010; Nagata et al., 2012; Matsuda et al., 2013). YKS is
also applied for symptomatic therapy of borderline personality
disorder (Miyaoka et al., 2008a), tardive dyskinesia (Miyaoka
et al., 2008b), treatment-resistant schizophrenia (Miyaoka
et al., 2009), Asperger’s disorder (Miyaoka et al., 2012),
postoperative delirium (Saito et al., 2010), preoperative anxiety
(Arai et al., 2014), and neuropathic pain (Nakamura et al.,
2009).
More recently, to facilitate greater understanding of the
neuropharmacological mechanisms underlying the clinical
efficacy of YKS, we reviewed the findings of basic studies. Our
research indicated that YKS has multiple neurotransmitter
mechanisms related to glutamatergic, serotonergic, cholinergic,
dopaminergic, adrenergic, and GABAergic neurotransmission,
and has neuroprotective effects and promoting effects
on neuroplasticity including neurogenesis (Ikarashi and
Mizoguchi, 2016). This suggested that YKS has multiple
neuropharmacological actions, which might be involved in
the various clinical benefits of YKS. Basic research has also
shown the psychopharmacological effects of YKS against
BPSD-like symptoms, other neurological symptoms, and
cognitive deficits. For example, YKS has been demonstrated
to ameliorate aggressiveness (Ikarashi et al., 2009; Iizuka et al.,
2010), hallucinations (Egashira et al., 2008; Ueki et al., 2015a,b),
anxiety (Mizoguchi et al., 2010b; Shoji and Mizoguchi, 2013),
dyskinesia (Sekiguchi et al., 2012), neuropathic pain (Suzuki
et al., 2012), and memory impairment (Ikarashi et al., 2009;
Tabuchi et al., 2009; Fujiwara et al., 2011; Nogami et al., 2013;
Uchida et al., 2013; Liu et al., 2014).
In this review, we aim to consolidate our understanding
of the relationship between the psychopharmacological effects
of YKS and the brain regions responsible for them. First,
the psychopharmacological effects of YKS are described, as
obtained primarily from animal studies, to show that YKS has
multiple psychopharmacological effects. Because these effects
are generally associated with brain regions responsible for
specific functions, we next looked at the relationship between
the psychopharmacological effects of YKS and the effects
in different brain regions. Finally, the present findings were
integrated into our understanding of the neuropharmacological
mechanisms of YKS. Ultimately, we aim for this review to
be utilized as a foundation for understanding the multiple
psychopharmacological actions of YKS on complex brain
networks (as circuits or pathways interlinking several brain
regions) related to dementia and BPSD.
METHODOLOGY
Manuscripts published from 2005 to 2016 describing the clinical
efficacy and psychopharmacological effects of YKS were selected
from PubMed database, the search term was “yokukansan”.
Articles related with physiology, pathophysiology, and animal
models of diseases were picked out manually. We excluded the
articles that were written in a language other than English.
YKS SOURCING AND
STANDARDIZATION
Yokukansan is composed of seven dried medicinal herbs;
Atractylodes lancea rhizome (4.0 g, rhizome of Atractylodes
lancea De Candolle, Compositae), Poria sclerotium (4.0 g,
sclerotium of Poria cocos Wolf, Polyporaceae), Cnidium rhizome
(3.0 g, rhizome of Cnidium officinale Makino, Umbelliferae),
Uncaria hook (3.0 g, thorn of Uncaria rhynchophylla Miquel,
Rubiaceae), Japanese Angelica root (3.0 g, root of Angelica
acutiloba Kitagawa, Umbelliferae), Bupleurum root (2.0 g, root of
Bupleurum falcatum Linné, Umbelliferae), and Glycyrrhiza (1.5 g,
root and stolon of Glycyrrhiza uralensis Fisher, Leguminosae).
Identification for each plant material and preparation of
YKS extract have been described previously (Ikarashi and
Mizoguchi, 2016). Three-dimensional high-performance liquid
chromatography has identified at least 25 ingredients in the
methanol fraction of YKS extract (Ikarashi and Mizoguchi, 2016).
PSYCHOPHARMACOLOGICAL EFFECTS
OF YKS
Effects of YKS on BPSD-Like Symptoms
Aggressiveness and Sociality
Oral administration of YKS ameliorated increased aggressiveness
and decreased social behaviors in transgenic mice expressing
human amyloid precursor protein (hAPP) (Fujiwara et al., 2011),
rats and mice subjected to thiamine deficiency (Ikarashi et al.,
2009; Iizuka et al., 2010; Yamaguchi et al., 2011), and serotonin
(5-HT)-deficient rats (Kanno et al., 2009), as measured by
social interaction tests. Further, YKS was shown to reduce the
enhanced aggression of zinc-deficient mice in resident-intruder
test (Takeda et al., 2012), as well as that of socially isolated mice,
as measured by the reaction to a wooden stick (Uchida et al.,
2009) or social interaction test (Nishi et al., 2012). In other
research, YKS ameliorated increased aggressive behavior in mice
intracerebroventricularly injected with amyloid β (Aβ) protein
without physical inhibition, whereas antipsychotics reduced
aggressive behavior but with concomitant suppression of motor
activity (Sekiguchi et al., 2009). They also demonstrated that
co-administration of YKS and donepezil ameliorated aggressive
behavior in the same animal model, with donepezil not lessening
the anti-aggressive effect of YKS, and YKS not interfering
with the inhibitory effect on acetylcholinesterase activity and
the improving effect on cognitive disturbance of donepezil
(Sekiguchi et al., 2011). These agents may, therefore, have
independent and complementary therapeutic effects on multiple
dementia symptoms.
Hallucinations
Several hallucinogenic compounds such as lysergic acid
diethylamide, N,N-dimethyltryptamine, and bufotenine, all
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with an indoleamine structure resembling 5-HT, have been
demonstrated to induce the head-twitch response in animals
(Nichols, 2004). In addition, agonistic action on central 5-HT2A
receptors evokes head-twitch (Lucki et al., 1984) and wet-dog
shake responses (Bedard and Pycock, 1977), suggesting that
these responses to stimulation of 5-HT2A receptors are good
behavioral markers for hallucinations in animals. In normal
mice, oral administration of YKS reduced head-twitch behavior
induced by treatment with the 5-HT2A receptor agonist 2,5-
dimethoxy-4-iodoamphetamine (DOI) (Egashira et al., 2008).
In stressed mice, isolation stress for 6 weeks aggravated the
hallucination-like behavior, and YKS reversed this aggravation,
which was thought to be mediated by additive and/or synergic
effects of Bupleurum root, Uncaria hook, Japanese Angelica root,
and Glycyrrhiza in YKS (Ueki et al., 2015b). A similar result was
seen in rats subjected to ischemia/reperfusion injury (Nogami
et al., 2011).
Anxiety
Oral YKS ameliorated anxiety-like behavior in normal mice
(Kamei et al., 2009; Shoji and Mizoguchi, 2013) and aged
rats (Mizoguchi et al., 2010b) in the elevated-plus maze.
Similar effects have also been demonstrated in rats subjected to
cerebrovascular ischemia in both light/dark box and elevated-
plus maze tests (Nogami et al., 2011), and fear-conditioned rats
during re-exposure to the context (Yamaguchi et al., 2012). In
addition, YKS ameliorated abnormal behavior in APP-Tg mice,
as shown by increased number of entry and prolonged time in
the open arm of an elevated-plus maze, suggesting that YKS
ameliorates disinhibition in APP-Tg mice (Tabuchi et al., 2009).
Sleep Disturbance
Yokukansan has also been shown to reverse the shortening
of sleep time induced by pentobarbital injection in socially
isolated mice (Egashira et al., 2011). Recently, using
electroencephalography and electromyography, Nagao et al.
(2014) investigated the effect of oral administration of YKS on
sleep disturbance in a rat model of cerebrovascular dementia.
Rats with cerebral ischemia had a higher total wakefulness
time and lower total non-rapid eye movement sleep, so it was
concluded that sleep disturbances were ameliorated by YKS.
More recently, Ogawa et al. (2016) examined the sleep-promoting
effect of YKS by thermography, which evaluates the decrease
in skin temperature of mice during sleep. The authors showed
that YKS effectively decreased skin temperature. This result
suggests sleep-promoting effect of YKS. They suggested direct
effects of Uncaria hook, Bupleurum root, Cnidium rhizome, and
Japanese Angelica root, together with indirect effects of Poria
sclerotium, Atractylodes Lancea rhizome, and Glycyrrhiza, for
the sleep-promoting effect of YKS.
Hyperlocomotion
Yokukansan has no effect on motor activity in general (Ikarashi
et al., 2009; Kanno et al., 2009; Tabuchi et al., 2009; Mizoguchi
et al., 2010b, 2011; Fujiwara et al., 2011; Nishi et al., 2012).
However, it has been reported to mitigate hyperlocomotor
activity in mice treated with methamphetamine (Makinodan
et al., 2009; Uchida et al., 2009) and in gerbils subjected to
ischemia/reperfusion injury (Liu et al., 2014).
Maladaptation
The effect of YKS on the adaptive response was examined
by using an automatic hole-board test in chronically stressed
mice (Tsuji et al., 2014). Thus, a restraint stress for 60 min
decreased the number of head-dipping behavior, which means
increased emotional response. However, this was not observed
in mice exposed to repeated stress for 14 days, suggesting
the development of adaptation by repeating stress for 60 min.
However, mice exposed to 240 min-stress for 14 days did
not show adaptation to the stress. This maladaptation was
ameliorated by YKS or 5-HT1A receptor agonist flesinoxan.
These findings suggest that YKS may facilitate stress adaptation
via alleviation of emotional abnormality under conditions of
excessive stress.
Prepulse Inhibition
A weaker prepulse is known to inhibit a subsequent stronger
stimulus pulse. This phenomenon is generally referred to
prepulse inhibition (PPI), which is the temporarily adaptive
response to a stronger startle-inducing sensory stimulus when
preceded by a weaker “warning” signal (Makinodan et al., 2009).
In the pathophysiology, reduced PPI (a startle response similar to
that observed without a prepulse) is a behavioral end-phenotype
of schizophrenia in humans and in animal models. In the
latter, reduced PPI is also observed in pups of dams injected
intraperitoneally with polyinosinic:polycytidylic acid (poly I:C),
a synthetic analog of double-stranded RNA that mimics the
in utero response to viral infection, and which indicates a possible
etiology of schizophrenia. Oral administration of YKS has been
reported to reverse this reduced PPI (Makinodan et al., 2009).
Effects of YKS on Non-BPSD Symptoms
Tardive Dyskinesia
Repeated injection of haloperidol into the thigh induces vacuous
chewing movement in rats, which is known as an index of tardive
dyskinesia. YKS alleviated haloperidol-induced vacuous chewing
movement (Sekiguchi et al., 2012).
Neuropathic Pain
Oral YKS improved filament-induced mechanical allodynia
and acetone-induced cold allodynia in rats with chronic
constriction injury (Suzuki et al., 2012). YKS also improved
mechanical allodynia through the regulation of interleukin 6 (IL-
6) expression in the spinal cord of mice with neuropathic pain
(Ebisawa et al., 2015).
Morphine Tolerance and Physical Dependency
An opioid analgesic morphine is often used to treat several types
of pain that is related to operation and cancer. It is well-known
that the prolonged use can induce analgesic tolerance, physical
dependence, and addiction. Nakagawa et al. (2012) demonstrated
that YKS alleviated tolerance and physical dependence induced
by repeated administration of morphine, without affecting the
analgesic effect in mice.
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Allergy/Atopic Dermatitis
Yokukansan inhibited development of atopic dermatitis-like
skin lesions in socially isolated NC/Nga mice by suppression
of scratching and grooming behaviors, inhibition of mast
cell and eosinophil infiltration, and enhancement of skin
moisture retention (Jiang et al., 2009; Funakushi et al., 2011).
Yamamura et al. (2014) also reported that YKS inhibited mast
cell degranulation, TNFα release from mast cell-like RBL-
2H3 basophil leukemia cells, and TNFα-induced intercellular
adhesion molecule-1 expression in human endothelial cells.
These ameliorative effects were not the actions on central nervous
system, but were thought to be indirectly mediated by the
psychopharmacological effects of YKS such as the anxiolytic
effect (Yamamura et al., 2014).
Effects of YKS on Cognitive Dysfunction
Yokukansan prevented cognitive disturbances in APP-Tg mice
(Tabuchi et al., 2009; Fujiwara et al., 2011), mice with
intracerebroventricular Aβ-injection (Sekiguchi et al., 2011), rats
subjected to cerebrovascular ischemia (Nogami et al., 2013) or
intracerebroventricular Aβ injection with ischemia/reperfusion
injury (Uchida et al., 2013), gerbils with cerebral ischemia (Liu
et al., 2014) and rats with thiamine-deficiency (Ikarashi et al.,
2009). YKS was also shown to ameliorate cognitive deficits in
animal models of schizophrenia, such as poly I:C-injected mice
(Makinodan et al., 2009), Gunn rats (Furuya et al., 2013), and
aged rats (Mizoguchi et al., 2011).
BRAIN REGIONS RESPONSIBLE FOR
THE PSYCHOPHARMACOLOGICAL
EFFECTS OF YKS
Cerebral Cortex
Areas not in sensory or motor areas of the cerebral cortex
are termed “association areas,” and are considered to integrate
higher cerebral functions such as cognition, judgment, memory,
language, and dense exercise. There are known parietal and
temporal association areas, and a frontal association area, the
latter of which includes the prefrontal cortex (PFC). The PFC
of rodents consists of several areas, including the prelimbic
and infralimbic cortexes, which are thought to be involved
in cognitive performance and emotional responses (Shoji and
Mizoguchi, 2013).
Orally administered YKS has been suggested to affect the
cerebral cortex. For example, histopathological examination
showed that YKS inhibited the concomitant degeneration of
neuronal and astroglial cells in the cerebral cortexes of thiamine-
deficient rats, as produced by a thiamine-deficient diet for
37 days; in that study, YKS ameliorated BPSD-like symptoms
such as aggressiveness and anxiety (Ikarashi et al., 2009). In vitro
primary culture studies using rat cortical astrocytes suggest that
YKS ameliorates the thiamine-deficient-induced dysfunction of
glutamate transport into astrocytes via increased expression of
glutamate transporters (Kawakami et al., 2009, 2010). In primary
cultured cortical neurons, YKS also inhibited glutamate-induced
neuronal death (Kawakami et al., 2011).
Several reports have demonstrated that the efficacy of YKS is
associated with its effects in the PFC. In socially isolated mice,
dietary supplementation with YKS increased the 5-HT1A receptor
density in the PFC, which was thought to mediate augmentation
of behavioral response (i.e., decreased rearing behavior) to the 5-
HT1A receptor agonist (±)-8-hydroxy-2-(dipropylamino)tetralin
hydrobromide (8-OH-DPAT) (Ueki et al., 2015a). YKS has
a partial agonistic action for 5-HT1A receptors (Terawaki
et al., 2010), and geissoschizine methyl ether (GM), an indole
alkaloid derived from Uncaria hook, has been identified as the
active ingredient responsible for the partial agonism of 5-HT1A
receptors by YKS (Nishi et al., 2012). Although speculative, the
up-regulatory effect of YKS on prefrontal 5-HT1A receptors leads
us to hypothesize that YKS has the actions to increase the target
molecule(s) and stimulate it for the effective amelioration of
psychological symptoms such as aggressiveness and anxiety.
The relationship between YKS and PFC has also been
demonstrated in 5-HT2A receptors. YKS has been shown to
downregulate 5-HT2A receptor expression in the PFCs and
reduce the DOI-induced hallucination-like behavior (head-
twitching) in normal mice (Egashira et al., 2008) and stressed
mice (Ueki et al., 2015b). It has been suggested that there
is a synergistic effect of Bupleurum root, Uncaria hook,
Japanese Angelica root, and Glycyrrhiza among seven constituent
components of YKS is suggested to be concerned in this
downregulation of 5-HT2A receptors (Ueki et al., 2015b). These
results indicate that the reduction of DOI-induced hallucination-
like behavior by YKS might involve down-regulation of 5-HT2A
receptors in the PFC. Taken together, the improving effects of
YKS on aggressive, hallucination-like, and anxiety-like behaviors
might be mediated by acting together with the effects on 5-HT1A
and 5-HT2A receptors in the PFC region.
In the PFC of aged rats, a decrease in the proliferation
and migration of neuronal stem/progenitor cells identified by
incorporation of bromodeoxyuridine was observed (Tanaka and
Mizoguchi, 2009). In addition, this decrease might be caused by
changes in a microenvironment formed by extracellular matrix,
because increased expression of aggrecan, a major molecule of
chondroitin sulfate proteoglycans, which are thought to inhibit
axonal growth, migration, and synaptic plasticity of neurons
(Perris and Johansson, 1990; Bradbury et al., 2002; Schwartz and
Domowicz, 2004), was also observed in the aged PFC. Both the
decrease in bromodeoxyuridine-labeled cells and the increase
in aggrecan expression in the PFC of aged rats were improved
by YKS treatment for 3 months, suggesting that activation
of neuroplasticity, including proliferation and migration, is
facilitated by the action of YKS in the PFC region.
In addition, the age-related working memory deficit is
suggested to be caused by reduced extracellular dopamine levels
in the prelimbic region of the PFC (Mizoguchi et al., 2009).
A similar causal relation between reversal learning deficit and
orbitofrontal regions of the PFC is suggested (Mizoguchi et al.,
2010a). YKS improved not only these working memory and
reversal learning deficits but also the decrease in dopamine
neurotransmission in the PFC structure (Mizoguchi et al., 2010b,
2011), and the improvement of the deficits was counteracted
by infusion of a dopamine D1 receptor antagonist SCH23390
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into these prefrontal cortical regions (Mizoguchi et al., 2011).
YKS may interact in the PFC to improve age-related learning
and memory deficits. Thus, YKS is thought to be effective for
cognitive deficits and obstinacy in aged subjects.
Aged rats also showed anxiety-like behaviors and decreased
5-HT release in the prelimbic region of the PFC, and YKS
improved these age-related changes (Mizoguchi et al., 2010a).
In other research, Shoji and Mizoguchi (2013) have shown the
relationships between the anxiolytic effects of YKS and the
PFC. Thus, YKS ameliorated restraint stress-induced anxiety and
increased c-Fos expression, a maker of neuronal activation, in the
prelimbic cortex of the PFC in young rats. This result supports
that the anxiolytic effect of YKS is related to its effects in the
prelimbic cortical region of the PFC.
Studies have indicated that GM reaches the brains of rats given
YKS orally by crossing the blood–brain barrier (BBB) (Imamura
et al., 2011; Kushida et al., 2013). In the autoradiography analysis
using tritium-labeled GM ([3H]GM) (Figure 1), we identified
that the frontal cortex, including the PFC, had the highest density
of specific binding for [3H]GM (Figure 2) (Mizoguchi et al.,
2014b). Candidate molecules of the binding sites were identified
by competition-binding assay, and included 5-HT1A, 5-HT2A,
5-HT2B, 5-HT2C, 5-HT7, D2, adrenergic α2A, and µ-opioid
receptors, and L-type Ca2+ channels. A similar result has been
obtained in a single-cell-based calcium imaging assay (Ueda
et al., 2011). Moreover, the [3H]GM signals were accumulated
in frontal cortical region in the microautoradiography analysis,
including neuron-like large cells. Taken together, these findings
suggest that GM specifically binds to the frontal cortex of rats, and
that GM expresses its several pharmacological actions through
5-HT receptors in the frontal cortex.
Limbic System
The limbic system is a generic term for a region that includes
the paleocortex, archipallium, mesocortex, and subcortical nuclei.
Here we include the amygdala, hippocampus, and corpus
callosum, which are related to emotion (delight, anger, sorrow
and pleasure) and short- and long-term memory.
Amygdala
Shoji and Mizoguchi (2013) showed that restraint stress induces
anxiety state and the increase in c-Fos expression in the
basolateral and medial amygdaloid nuclei in rats. YKS suppressed
these stress-induced phenotypes, suggesting that these areas are
related to the anxiolytic effect of YKS.
Hippocampus
Neuronal and astroglial degenerations, as described in Section
“Effects of YKS on BPSD-Like Symptoms,” were also observed
in the hippocampus of thiamine-deficient rats, and these
degenerations were ameliorated by YKS (Iizuka et al., 2010).
YKS administration for 14 days improved spatial memory
impairment induced by combination of intracerebroventricular
Aβ injection and ischemia/reperfusion injury in rats (Uchida
et al., 2013). This effect may be mediated by increasing
acetylcholine release via the regulation of dynamin 1 in
the hippocampus. The same regimen of YKS also improved
spatial memory disturbance, reduced acetylcholine release, and
neuronal apoptosis in the hippocampal CA1 subfield of rats
subjected to ischemia/reperfusion injury (Nogami et al., 2013).
Oral administration of YKS for 30 days also ameliorated not
only locomotor hyperactivity and memory impairment but
also hippocampal CA1 neuronal death, inflammatory response,
and oxidative DNA damage induced by ischemia/reperfusion
injury in gerbils (Liu et al., 2014), suggesting that YKS
inhibits the inflammatory response, oxidative stress, and
subsequent neuronal death in the hippocampus induced by
transient ischemia. YKS has also been suggested to prevent
cognitive deficits through suppression of microglia activation and
promotion of neurogenesis in the hippocampal dentate gyrus of
Gun rats, an established animal model of schizophrenia (Furuya
et al., 2013).
In zinc-deficient rats, a model of neurological disease, YKS
attenuated the increased extracellular glutamate concentration
in the hippocampus (Takeda et al., 2008). As the underlying
mechanisms, glutamate release from the presynaptic terminal in
the hippocampal CA3 subfield was increased by tetanic stimuli at
the dentate granule cell layer in the hippocampal slice prepared
from zinc-deficient rat, compared with controls. This increase
was attenuated in the preparations from rats orally administered
YKS (Takeda et al., 2008).
In other research, pretreatment with oral YKS 1 h before
stress exposure was demonstrated to normalize the stress-
induced elevation of plasma corticosterone, a stress hormone
that is cytotoxic toward neurons (Shimizu et al., 2015a,b).
Corticosterone-induced cytotoxicity of mouse embryonic
hippocampal neurons is also reported to be protected by
treatment with YKS (Nakatani et al., 2014).
Decreased proliferation and migration of neuronal stem cells
and increased expression of aggrecan were also observed in the
hippocampus of aged rats, and YKS was shown to improve
these changes (Tanaka and Mizoguchi, 2009). The promoting
effect of YKS was also demonstrated in oligodendrocytes,
where YKS promoted the proliferation and differentiation of
oligodendrocytes in an experiment that used purified mouse
oligodendrocyte precursor cells. GM was identified as the
active ingredient responsible for this effect (Ueki et al., 2014).
Elsewhere, this in vitro effect has been supported in in vivo
research by Morita et al. (2014), who examined the effect of GM
on demyelination in cuprizone-treated mice. They demonstrated
that GM significantly increased bromodeoxyuridine-labeled
GSTpi+ mature oligodendrocytes and reversed the decrease in
myelin basic protein immunoreactivity. These results indicate
that GM is likely to promote the proliferation of oligodendrocytes
and their differentiation into mature oligodendrocytes.
It is known that Glycyrrhiza-derived glycyrrhizin is
metabolized to 18β-glycyrrhetinic acid (GA) by β-glucuronidase
activity in the enteric bacteria. This metabolite is absorbed
into the systemic circulation, then distributes to the brain
(Tabuchi et al., 2012). Given that several in vitro studies
suggest that GA is a potent active ingredient, we examined
whether GA specifically binds to the brain tissue using [3H]GA
(Figure 1). Autoradiography found that the hippocampus
(including the dentate gyrus) is the highest density of
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FIGURE 1 | Chemical structures of tritium-labeled geissoschizine methyl ether ([3H]GM) and 18β-glycyrrhetinic acid ([3H]GA). For [3H]GM, three tritium
atoms were introduced into the methyl group of the methyl ester in its structure; For [3H] GA, one tritium atom was introduced at the third position in its structure.
FIGURE 2 | Autoradiograms to determine specific bindings of tritium-labeled geissoschizine methyl ether ([3H]GM) and 18β-glycyrrhetinic acid
([3H]GA) in rat brain slices. Freshly frozen sections of rat brain were reacted with [3H]GM or [3H]GA and exposed to a tritium-sensitive imaging plate. After
exposure, the plates were analyzed in an imaging analyzer to generate autoradiograms. Specific binding sites of [3H]GM were densely detected in the frontal cortex
and those of [3H]GA were in the hippocampus. These findings are cited from the following articles: Mizoguchi et al. (2014a) for [3H]GM; Mizoguchi et al. (2014b) for
[3H]GA.
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specific binding for [3H]GA (Figure 2) (Mizoguchi et al.,
2014a). The candidate molecules of the binding sites were not
steroid receptors, gap junctions, glutamate transporters, and
glutamate receptors. Moreover, in the microautoradiography
analysis, [3H]GA distributed in hippocampal astrocyte-like
cells containing 11β-hydroxysteroid dehydrogenase type-1
(11β-HSD1, Mizoguchi et al., 2014a). These results suggest that
GA specifically binds to the hippocampus of rats, and that GA
expresses its several pharmacological actions through 11β-HSD1
in astrocytes.
Corpus Callosum
The corpus callosum connects the right and left cerebral
hemisphere. The neural fibers contained in it facilitate
interhemispheric cerebral communication. In adult mice,
acute stress increased corticosterone in the plasma and decreased
glucocorticoid receptor (GR) protein, but did not change its
mRNA expression in oligodendrocytes of the corpus callosum
(Shimizu et al., 2015b). MicroRNAs (miRs) are non-coding
RNAs that inhibit the translation and/or decrease the stabilities
of their target mRNAs, ultimately decreasing target protein
expression (Carthew, 2006; Wang et al., 2007). MiRs also
regulate development and differentiation of neurons (Stefani and
Slack, 2008; Chiu et al., 2014). MiR-124a is a candidate negative
regulator of GR expression in the brain (Vreugdenhil et al., 2009),
and Shimizu et al. (2015b) showed that acute stress increased its
expression in oligodendrocytes of the corpus callosum. In a drug
treatment study, YKS normalized the stress-induced changes in
plasma corticosterone, GR protein, and miR-124a expression,
although GR mRNA level was not significantly changed. Thus,
YKS may alleviate the stress-induced decrease in GR protein by
downregulating miR-124a expression.
Basal Ganglia
Generally, the term basal ganglia is applied to the caudate
nucleus, putamen, and globus pallidus, and functionally related
to the substantia nigra and subthalamic nucleus. The caudate
nucleus and the putamen are called the striatum (Ikarashi and
Maruyama, 1999).
Striatum
The vacuous chewing movement in rats induced by haloperidol
can be ameliorated by oral administration of YKS (Sekiguchi
et al., 2012). Real-time PCR and microdialysis analyses showed
that YKS increased mRNA expression of an astroglial glutamate
transporter, glutamate transporter 1 in the striatum, and
decreased haloperidol-evoked elevation of striatal glutamate
release. This result suggests that the amelioration by YKS
against vacuous chewing involved the inhibition of excessive
extracellular glutamate through the facilitation of striatal
glutamate transporter expression.
Nigrostriatum
Unilateral nigrostriatal lesions by microinjecting 6-hydroxy-
dopamine (6-OHDA) into the rat medial forebrain bundle
decreased tyrosine hydroxylase immunoreactivity (i.e., dopamine
loss) in the striatum, which has been established as an animal
model of Parkinson’s disease (Ishida et al., 2016). Repeated
intraperitoneal injection of L-3,4-dihydroxyphenylalanine
(L-DOPA) to the 6-OHDA-lesioned rats induced abnormal
rotational and axial movements. YKS enhanced these abnormal
movements. This might be due to the augmentation of dopamine
supplementation via inhibition of catechol-O-methyltransferase
in the striatum. GM and corynoxeine, which are alkaloids in
Uncaria hook, are suggested to contribute to the inhibitory
effects of YKS (Ishida et al., 2016).
Doo et al. (2010) investigated the neuroprotective effects of
Korean Yi-Gan San (YGS), which is composed of nine medical
herbs (the seven medical herbs used in YKS in Japanese Kampo,
plus Ponciri fructus and Magnoliae cortex). They used a model
of in vitro and in vivo 1-methyl-4-phenylpyridine (MPP+)/1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridene (MPTP)-induced
cytotoxicity, and showed that pretreatment of SH-SY5Y human
neuroblastoma cells with Korean YGS protected against MPP+-
induced cell degeneration and decreased caspase-3 activity
concomitant with increased phosphorylated Akt expression.
LY294002, the inhibitor of phosphatidyl-inositol 3-kinase
(PI3K)/Akt, reduced the effectiveness of Korean YGS. In
MPTP-treated mice, Korean YGS treatment regained abnormal
movement, and also inhibited nigrostriatal dopaminergic
neuronal loss. From these results, it was concluded that Korean
YGS can rescue dopaminergic degeneration from MPP+/MPTP
cytotoxicity through PI3K/Akt signaling activation. A similar
effect of YKS on the PI3K/Akt pathway has been demonstrated
(Kubota et al., 2013). Thus, YKS and Korean YGS might
each prevent dopaminergic neuronal loss in the nigrostriatal
region.
Diencephalon
The diencephalon including the thalamus and hypothalamus
plays a role related to various vital functions. In thiamine-
deficient rats used to assess the effects of YKS on BPSD-
like behaviors, the extracellular glutamate concentration was
increased in vulnerable brain regions, including the thalamus
(Langlais and Zhang, 1993). In the ventral posteromedial
thalamus, this elevation was normalized by oral administration
of YKS (Ikarashi et al., 2009), indicating that YKS might affect
the thalamus. Furthermore, GR signaling has been known to
regulate the hypothalamic–pituitary–adrenal axis activity. The
axis activation also affects GR expression. YKS normalized a
stress-induced decrease in GR protein in the paraventricular
nucleus (Shimizu et al., 2015a,b). YKS also decreased miR-
18, another negative regulator for GR expression in the
paraventricular nucleus, although GR mRNA levels were not
significantly changed (Shimizu et al., 2015a,b). These results
suggest that YKS normalizes the stress-induced decrease in GR
protein in the paraventricular nucleus by downregulating miR-18
levels and thereby disinhibiting mRNA translation.
Brainstem
The brainstem includes the medulla oblongata, pons, and
midbrain, and research has examined the effects of YKS on
morphological damage in the medulla-pons of thiamine-deficient
rats. Sponge-like degeneration was detected in this area by light
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FIGURE 3 | Multiple psychopharmacological effects of yokukansan (YKS) and the brain regions affected. YKS consists of seven medicinal herbs, so has
ameliorative effects on aggression, hallucination, anxiety, and so on, which are related to the specific brain regions. Other effects include amelioration of
hyperlocomotion, maladaptation, and reduced prepulse inhibition. Other brain regions include the corpus callosum, thalamus, and hypothalamus.
microscopy (Ikarashi et al., 2009), and the neuronal and astroglial
degenerations were detected in the vestibular nucleus by electron-
microscopy (Iizuka et al., 2010). Both changes were inhibited by
treating YKS.
Nakagawa et al. (2012) have reported that repeated morphine
treatment causes α2A-adrenoceptor reduction in the medulla-
pons of mice, and this was prevented by Glycyrrhiza and
Uncaria hook, as well as YKS. The α2A-adrenoceptor antagonist
yohimbine showed similar effects to YKS. Moreover, YKS,
Glycyrrhiza, and Uncaria hook had antagonistic effects
on the α2A-adrenoceptors. These results suggested that
Glycyrrhiza and Uncaria hook in YKS inhibit tolerance and
physical dependence induced by repeated administration of
morphine in mice (described above) through their ability
to block α2A-adrenoceptors, thereby preventing decreased
membrane expression of the receptors in the medulla-pons.
Glycyrrhiza-derived GA and Uncaria hook-derived GM are
thought to be the active ingredients responsible for the efficacy of
YKS.
Spinal Cord
Single administration of YKS has been reported to inhibit
allodynia in rats subjected to chronic constriction injury (Suzuki
et al., 2012). In vivo microdialysis showed that YKS inhibited
brush- or acetone-induced increases in glutamate concentrations
in the cerebrospinal fluid, and the antiallodynic actions of YKS
were counteracted by intrathecal injection of the glutamate
transporter inhibitor, suggesting that the antiallodynic actions
are associated with attenuation of glutamate neurotransmission
via glutamate transporter activation in the spinal cord. We
demonstrated that GA was responsible for the ameliorating
effect of YKS on glutamate transport dysfunction via glutamate
transporter activation in astrocytes (Kawakami et al., 2009,
2010), and also that GA was detected in the cerebrospinal fluid
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of rats administered YKS orally (Tabuchi et al., 2012). Thus,
the analgesic effect of YKS may be from inhibition of pain
transmission to the upper central nervous system through the
suppression of excess glutamate release from primary afferent
fibers via glutamate transporter activation in astrocytes of the
spinal cord.
In partial sciatic-nerve ligated mice, Ebisawa et al. (2015)
showed that YKS relieved mechanical allodynia and inhibited IL-
6 mRNA expression (a mediator of pain) in the spinal cords.
These results indicated that the anti-nociceptive action of YKS
might be mediated by suppressed IL-6 mRNA expression in
spinal astrocytes and microglias. They suggest that Atractylodes
lancea rhizome may be the active component.
CONCLUSION
Dementia is a most problematic age-related neurodegenerative
disorder of modern society, with a prevalence exceeding 4.62
million people in Japan. Dementia is often complicated by BPSD,
and many clinical trials have shown the usefulness of YKS for the
treatment of related aggressiveness, agitation, and hallucination,
without producing severe side effects. However, several adverse
drug reactions have been reported; they occurred in 136 cases
(4.3%) in total among 3,156 patients treated with YKS (Hisada
et al., 2014). In addition, pseudohyperaldosteronism should be
paid attention because YKS contains Glycyrrhiza. In parallel
with clinical trials, basic research can now explain several of
the neuropsychopharmacological effects of YKS. In the present
review, we described the multiple psychopharmacological effects
of YKS, including the ameliorative effects on aggressiveness,
hallucination, anxiety, sleep disturbance, hyperlocomotion,
maladaptation, reduced PPI, tardive dyskinesia, neuropathic
pain, morphine dependence, allergy/atopic dermatitis, and
cognitive dysfunction in experimental animals. Following this,
we attempted to identify evidence for the relationship between
the psychopharmacological effects and the brain regions that are
related to the effects, which showed that YKS affected the cerebral
cortex, hippocampus, striatum, thalamus, hypothalamus, corpus
callosum, and spinal cord, which are all involved in behavioral,
psychiatric, cognitive, and perceptional dysfunctions (Figure 3).
Given that YKS is composed of seven medicinal herbs that
contain a multitude of ingredients, these findings suggest
that its psychopharmacological effects might be attributable
to multiple rather than individual brain regions. Among the
active ingredients of YKS, GM and GA seem to predominate
(Figures 1–3). GM, which comes from Uncaria hook, is
suggested to act predominantly in the frontal cortical regions
of the cerebral cortex, where it behaves as a partial agonist
of 5-HT1A receptors, and thereby mediates the anti-aggressive
and anxiolytic effects of YKS. GA, which is the major
metabolite of glycyrrhizin in Glycyrrhiza, is suggested to act
predominantly in the hippocampus, where it might enhance
glutamate uptake into astrocytes via activation of glutamate
transporters.
Brain function is regulated or controlled by a complex
neural network that involves several neurotransmitter pathways,
with glutamate, 5-HT, noradrenaline, dopamine, and GABA
in the particular brain regions, all mediating neuronal signals
(Cooper et al., 1991; Ikarashi and Maruyama, 1999). Recently,
we reviewed the basic research into YKS, including its multiple
neuropharmacological mechanisms related to glutamatergic,
serotonergic, cholinergic, dopaminergic, adrenergic, and
GABAergic neurotransmission; the ingredients active on
those neurotransmitter systems; their pharmacokinetics;
and the possible mechanisms of action of YKS (Ikarashi
and Mizoguchi, 2016). As described in the present review,
various brain regions would no doubt be affected by oral
administration of YKS. Although it remains unknown whether
the psychopharmacological effects of YKS reflect active brain
areas directly or indirectly, our two reviews into YKS should
help facilitate a more holistic understanding of the mechanisms
underlying its clinical efficacy. To obtain more detail about the
beneficial effects of YKS, future research aims to identify the
active ingredients and study their additive and/or synergistic
effects in the neural network. Currently, it appears that at
least GM and GA act in the cerebral cortex and hippocampus,
respectively, where they contribute to the observed beneficial
effects of YKS (Mizoguchi et al., 2014a,b). In conclusion, this
review provides fundamental information about the multiple
psychopharmacological effects of YKS and their related brain
regions, which should help inform clinical practice and guide
future research.
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